Search
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTocofersolan
go.drugbank.com/drugs/DB11635ApprovedD-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis . Cholestasis is the reduction or stoppage of...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNomegestrol
go.drugbank.com/drugs/DB11636ApprovedNomegestrol is an ingredient in the EMA-authorised product Zoely.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDelamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall . It is used in the treatment of multidrug-resistant and extensively dru...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalVinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent tha...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCurcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalCurcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglyce...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalFruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalLupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalMyelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors